Sequenta, Inc. Expands Sample Types Accepted for ClonoSIGHT™ MRD Test for Leukemia and Lymphoma

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Sequenta, Inc. today announced that the sample types eligible for analysis with its ClonoSIGHT™ minimal residual disease (MRD) test for leukemia and lymphoma have been expanded to include formalin-fixed, paraffin-embedded (FFPE) tissue and bone marrow aspirate slides. This advancement allows the test to be performed on the diagnostic samples most commonly available from pathology labs.

Help employers find you! Check out all the jobs and post your resume.